Pd/Pa fluctuation with continuous ATP administration indicates inaccurate FFR measurement caused by insufficient hyperemia.
Adenosine triphosphate
Fluctuation
Fractional flow reserve
Hyperemia
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
received:
11
12
2023
accepted:
03
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
aheadofprint
Résumé
Continuous intravenous adenosine triphosphate (ATP) administration is the standard method for inducing maximal hyperemia in fractional flow reserve (FFR) measurements. Several cases have demonstrated fluctuations in the ratio of mean distal coronary pressure to mean arterial pressure (Pd/Pa) value during ATP infusion, which raised our suspicions of FFR value inaccuracy. This study aimed to investigate our hypothesis that Pd/Pa fluctuations may indicate inaccurate FFR measurements caused by insufficient hyperemia. We examined 57 consecutive patients with angiographically intermediate coronary lesions who underwent fractional flow reverse (FFR) measurements in our hospital between November 2016 and September 2018. Pd/Pa was measured after continuous ATP administration (150 μg/kg/min) via a peripheral forearm vein for 5 min (FFR
Identifiants
pubmed: 38981910
doi: 10.1007/s00380-024-02438-x
pii: 10.1007/s00380-024-02438-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Japan KK, part of Springer Nature.
Références
Pijls NH, Van Gelder B, Van der Voort P, Peels K, Bracke FA, Bonnier HJ, el Gamal MI (1995) Fractional flow reserve. a useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 92:3183–3193
doi: 10.1161/01.CIR.92.11.3183
pubmed: 7586302
Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van’t Veer M, Pijls NH (2010) Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 55:2816–2821
doi: 10.1016/j.jacc.2009.11.096
pubmed: 20579537
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF, FAME 2 Trial Investigators (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991–1001
doi: 10.1056/NEJMoa1205361
pubmed: 22924638
Tanaka N, Nakamura M, Akasaka T, Kadota K, Uemura S, Amano T, Shiode N, Morino Y, Fujii K, Hikichi Y, CVIT-DEFER Registry Investigators (2017) One-year outcome of fractional flow reserve-based coronary intervention in Japanese daily practice-CVIT-DEFER registry. Circ J 81:1301–1306
doi: 10.1253/circj.CJ-16-1213
pubmed: 28450667
Toth GG, Johnson NP, Jeremias A, Pellicano M, Vranckx P, Fearon WF, Barbato E, Kern MJ, Pijls NH, De Bruyne B (2016) Standardization of fractional flow reserve measurements. J Am Coll Cardiol 68:742–753
doi: 10.1016/j.jacc.2016.05.067
pubmed: 27515335
Johnson NP, Johnson DT, Kirkeeide RL, Berry C, De Bruyne B, Fearon WF, Oldroyd KG, Pijls NHJ, Gould KL (2015) Repeatability of fractional flow reserve despite variations in systemic and coronary hemodynamics. JACC Cardiovasc Interv 8:1018–1027
doi: 10.1016/j.jcin.2015.01.039
pubmed: 26205441
Matsumoto H, Nakatsuma K, Shimada T, Ushimaru S, Mikuri M, Yamazaki T, Matsuda T (2014) Effect of caffeine on intravenous adenosine-induced hyperemia in fractional flow reserve measurement. J Invasive Cardiol 26:580–585
pubmed: 25363999
Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD (1990) Effects of adenosine on human coronary arterial circulation. Circulation 82:1595–1606
doi: 10.1161/01.CIR.82.5.1595
pubmed: 2225364
Seto AH, Tehrani DM, Bharmal MI, Kern MJ (2014) Variations of coronary hemodynamic responses to intravenous adenosine infusion: implications for fractional flow reserve measurements. Catheter Cardiovasc Interv 84:416–425
doi: 10.1002/ccd.25305
pubmed: 24282074
Zhang Y, Wernly B, Cao X, Mustafa SJ, Tang Y, Zhou Z (2021) Adenosine and adenosine receptor-mediated action in coronary microcirculation. Basic Res Cardiol 116:22
doi: 10.1007/s00395-021-00859-7
pubmed: 33755785
pmcid: 7987637
Ho MF, Low LM, Rose’Meyer RB (2016) Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension. PLoS ONE 11:e0150021
doi: 10.1371/journal.pone.0150021
pubmed: 26907173
pmcid: 4764345
Bender SB, Tune JD, Borbouse L, Long X, Sturek M, Laughlin MH (2009) Altered mechanism of adenosine-induced coronary arteriolar dilation in early-stage metabolic syndrome. Exp Biol Med (Maywood) 234:683–692
doi: 10.3181/0812-RM-350
pubmed: 19307464
Zhou Z, de Wijs-Meijler D, Lankhuizen I, Jankowski J, Jankowski V, Jan Danser AH, Duncker DJ, Merkus D (2013) Blunted coronary vasodilator response to uridine adenosine tetraphosphate in post-infarct remodeled myocardium is due to reduced P1 receptor activation. Pharmacol Res 77:22–29
doi: 10.1016/j.phrs.2013.08.007
pubmed: 23994209
De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter H, Van Crombrugge P, Heyndrickx GR, Wijns W (2001) Fractional flow reserve in patients with prior myocardial infarction. Circulation 104:157–162
doi: 10.1161/01.CIR.104.2.157
pubmed: 11447079
Kofflard MJ, Michels M, Krams R, Kliffen M, Geleijnse ML, Ten Cate FJ, Serruys PW (2007) Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J 15:209–215
doi: 10.1007/BF03085982
pubmed: 17612685
pmcid: 1896141
Jang HJ, Koo BK, Lee HS, Park JB, Kim JH, Seo MK, Yang HM, Park KW, Nam CW, Doh JH, Kim HS (2013) Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur Heart J 34:2055–2062
doi: 10.1093/eurheartj/eht040
pubmed: 23396491
Tanaka N, Takahashi Y, Ishihara H, Kawakami T, Ono H (2015) Usefulness and safety of intracoronary administration of nicorandil for evaluating fractional flow reserve in Japanese patients. Clin Cardiol 38:20–24
doi: 10.1002/clc.22344
pubmed: 25626396
pmcid: 6711086
Kato D, Takashima H, Waseda K, Kurita A, Kuroda Y, Kosaka T, Kuhara Y, Ando H, Maeda K, Kumagai S, Sakurai S, Suzuki A, Toda Y, Watanabe A, Sato S, Fujimoto M, Mizuno T, Amano T (2015) Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements. Heart Vessel 30:477–483
doi: 10.1007/s00380-014-0508-5
Markham A, Plosker GL, Goa KL (2000) Nicorandil. an updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 60:955–974
doi: 10.2165/00003495-200060040-00007
pubmed: 11085202
Ishibuchi K, Fujii K, Otsuji S, Takiuchi S, Hasegawa K, Tamaru H, Ishii R, Yasuda S, Nakabayashi S, Yamamoto W, Kusumoto H, Taniguchi Y, Kakishita M, Shimatani Y, Higashino Y (2019) Utility and validity of intracoronary administration of nicorandil alone for the measurement of fractional flow reserve in patients with intermediate coronary stenosis. Circ J 83:2010–2016
doi: 10.1253/circj.CJ-19-0421
pubmed: 31413232
Takami H, Sonoda S, Muraoka Y, Sanuki Y, Kashiyama K, Fukuda S, Oginosawa Y, Tsuda Y, Araki M, Otsuji Y (2017) Impact of additional intracoronary nicorandil administration during fractional flow reserve measurement with intravenous adenosine 5’-triphosphate infusion. J Cardiol 69:119–124
doi: 10.1016/j.jjcc.2016.01.018
pubmed: 26947100
Matsumoto H, Mikuri M, Masaki R, Tanaka H, Ogura K, Arai T, Sakai R, Oishi Y, Okada N, Shinke T (2020) Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: comparison with intracoronary papaverine. Int J Cardiol 314:1–6
doi: 10.1016/j.ijcard.2020.05.013
pubmed: 32387252